Key clinical point: The marked gender difference in HFpEF clinical outcomes in response to sacubitril/valsartan has nothing to do with the medication’s impact on NT-proBNP.
Major finding: Women on sacubitril/valsartan get a 27% reduction in cardiovascular death and heart failure hospitalization.
Study details: This double-blind, randomized, multicenter trial included nearly 5,000 HFpEF patients assigned to sacubitril/valsartan or valsartan and followed for a median of 34 months.
Disclosures: The presenter reported no financial conflicts regarding the Novartis-funded PARAGON-HF trial.
Cunningham JW. ACC 2020, Abstract 412-08.